Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   43206   clinical trials with a EudraCT protocol, of which   7151   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-001275-50
    Sponsor's Protocol Code Number:IM101-550
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-11-05
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2015-001275-50
    A.3Full title of the trial
    A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naive
    Studio clinico di Fase 3B, randomizzato in doppio cieco per valutare l'efficacia e la sicurezza di abatacept SC in combinazione con metotressato verso metotressato in monoterapia nel raggiungere la remissione clinica in pazienti adulti con artrite reumatoide precoce mai trattati con metotressato.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Effects of abatacept in patients who have recently been diagnosed with rheumatoid arthritis.
    Effetti di abatacept in pazienti ai quali ¿ stata recentemente diagnosticata l¿artrite reumatoide.
    A.3.2Name or abbreviated title of the trial where available
    ND
    ND
    A.4.1Sponsor's protocol code numberIM101-550
    A.5.1ISRCTN (International Standard Randomised Controlled Trial) NumberISRCTN00000000
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT00000000
    A.5.3WHO Universal Trial Reference Number (UTRN)U1111-1168-2972
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBristol-Myers Squibb International Corporation
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBristol-Myers Squibb International Corporation
    B.5.2Functional name of contact pointGCT-SU
    B.5.3 Address:
    B.5.3.1Street AddressParc de l'Alliance - Avenue de Finlande, 4
    B.5.3.2Town/ cityBraine-l'Alleud
    B.5.3.3Post code1420
    B.5.3.4CountryBelgium
    B.5.4Telephone number000000
    B.5.5Fax number000000
    B.5.6E-mailclinical.trials@bms.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAbatacept
    D.3.2Product code [BMS-188667]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNABATACEPT
    D.3.9.1CAS number 332348-12-6
    D.3.9.2Current sponsor codeBMS-188667
    D.3.9.3Other descriptive nameND
    D.3.9.4EV Substance CodeSUB20635
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number125
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeproteina di fusione
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Methotrexate Ebewe
    D.2.1.1.2Name of the Marketing Authorisation holderEbewe
    D.2.1.2Country which granted the Marketing AuthorisationPoland
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMethotrexate
    D.3.2Product code [na]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMETHOTREXATE
    D.3.9.2Current sponsor codena
    D.3.9.3Other descriptive nameMETHOTREXATE
    D.3.9.4EV Substance CodeSUB08856MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Methotrexate Ebewe
    D.2.1.1.2Name of the Marketing Authorisation holderEBEWE Pharma
    D.2.1.2Country which granted the Marketing AuthorisationAustria
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMethotrexate
    D.3.2Product code [na]
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMETOTREXATO
    D.3.9.2Current sponsor codend
    D.3.9.3Other descriptive nameMETHOTREXATE
    D.3.9.4EV Substance CodeSUB08856MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Early Rheumatoid Arthritis
    Artrite Reumatoide Precoce
    E.1.1.1Medical condition in easily understood language
    Early Rheumatoid Arthritis
    Artrite Reumatoide Precoce
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.1
    E.1.2Level PT
    E.1.2Classification code 10039073
    E.1.2Term Rheumatoid arthritis
    E.1.2System Organ Class 10028395 - Musculoskeletal and connective tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective for this study is to compare the clinical efficacy of
    weekly abatacept in combination with MTX to MTX alone in achieving
    Remission, defined as SDAI = 3, at Week 24.
    L'obiettivo primario di questo studio ¿ quello di confrontare l'efficacia clinica di abatacept settimanale in combinazione con MTX verso MTX da solo nel raggiungere la remissione, definita come SDAI = 3, alla settimana 24.
    E.2.2Secondary objectives of the trial
    1) To compare the efficacy of weekly abatacept + MTX to MTX alone in
    achieving remission by DAS28-CRP Remission criteria at Week 24.
    2) To compare the efficacy of weekly abatacept + MTX to MTX alone in
    achieving remission by SDAI remission criteria at Week 52.
    3) To compare the efficacy of weekly abatacept + MTX to MTX alone in
    reducing joint damage by X-ray at Week 52.
    4) To compare the efficacy of weekly abatacept + MTX to MTX alone in
    achieving remission by Boolean remission criteria at Week 52.
    1) Confrontare l'efficacia di abatacept settimanale + MTX verso MTX da solo nel raggiungere la remissione in base a criteri di remissione DAS28 PCR alla settimana 24.
    2) Confrontare l'efficacia di abatacept settimanale + MTX verso MTX da solo nel raggiungere la remissione in base a criteri di remissione DAS28 PCR alla settimana 52.
    3) Confrontare l'efficacia di abatacept settimanale + MTX verso MTX da solo nel ridurre il danno articolare valutato radiograficamente alla settimana 52.
    4) Confrontare l'efficacia di abatacept settimanale + MTX verso MTX da solo nel raggiungere la remissione in base ai criteri di remissione Boolean alla settimana 52.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Other types of substudies
    Specify title, date and version of each substudy with relative objectives: The MRI sub-study is presented in section 5.4.1.2 of the original IM101-550 protocol dated 08-MAY-2015.
    MRI will be performed as a sub-study on about 80 subjects from selected qualified sites in selected countries. The purpose of this sub-study is to
    further inform the mechanism of action and efficacy of abatacept in Early RA by obtaining sensitive imaging at early time-points prior to those when traditional x-ray imaging would be expected to demonstrate significant change due to disease.

    Altre tipologie di sottostudi
    specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: Nella sezione 5.4.1.2 del protocollo IM101-550 datato 08-mag-2015 viene presentato il sotto-studio sulla RMN.

    La RMN sar¿ eseguita nell'ambito di un sotto-studio su circa 80 soggetti selezionati in centri qualificati in altrettanti paesi selezionati (solo USA come specificato nel protocollo). Lo scopo di questo sotto-studio ¿ quello di avere ulteriori informazioni sul meccanismo d'azione e sull'efficacia di abatacept nell'artrite reumatoide precoce ottenendo immagini sensibili in momenti temporali anticipati rispetto a quando le immagini radiografiche tradizionali sarebbero in grado di dimostrare cambiamenti significativi legati alla malattia.
    E.3Principal inclusion criteria
    a) Subjects have early RA, defined as diagnosis made by the ACR/EULAR
    2010 criteria for the classification of RA within the past 6 months
    b) Subjects must meet at least one of the following criteria:
    i) CRP > 0.3mg/dL (ULN)
    ii) ESR= 28mm/hr
    c) Subjects have at least 3 tender joints and at least 3 swollen joints
    using the 28 Joint Count Assessment at both screening and Day 1
    (Appendix 11)
    d) Subjects are positive for anti-citrullinated protein antibodies (ACPA)
    e) Subjects have an SDAI > 11
    a) Soggetti con artrite reumatoide precoce, definite come diagnosi second i criteri ACR/EULAR 2010 per la classificazione di Artrite Reumatoide negli ultimi 6 mesi
    b) Soggetti devono soddisfare almeno uno dei seguenti criteri:
    i) CRP > 0.3mg/dL (ULN)
    ii) ESR = 28mm/hr
    c) I soggetti devono avere almeno 3 articolazioni dolenti e almeno 3 articolazioni tumefatte utilizzando la valutazione 28 Joint Count Assessment sia allo screening che al Giorno 1(Appendice 11)
    d) I soggetti positivi per gli anticorpi proteina anti proteina citrullinate (ACPA)
    e) Soggetti con un valore sulla scala SDAI > 11
    E.4Principal exclusion criteria
    a) Subjects at risk for tuberculosis
    b) Subjects with recent acute infection
    c) Subjects with history of chronic or recurrent bacterial, viral or
    systemic fungal infections.
    d) Subjects who have present or previous malignancies, except
    documented history of cured non-metastatic squamous or basal skin cell
    carcinoma, or cervical carcinoma in situ
    e) Creatinine clearance < 40 mL/min (Cockroft-Gault formula)
    a) Soggetti a rischio di tuberculosi
    b) Soggetti con infezione acuta recente
    c) Soggetti con storia di infezioni batterica cronica o ricorrente, virale o fungina sistemica.
    d) Soggetti che hanno tumori presenti o precedenti, ad eccezione di storia documentata di carcinoma a cellule squamose della pelle o basale non metastatico curato o carcinoma in situ della cervice.
    e) Creatinina clearance < 40 mL/min (Formula di Cockroft-Gault)
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is the proportion of subjects in SDAI Remission at Week 24.
    L'endpoint primario di efficacia è la proporzione di soggetti in Remissione SDAI alla settimana 24.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 24
    Settimana 24
    E.5.2Secondary end point(s)
    The secondary endpoints below will be assessed in the order below in a
    hierarchical fashion after the primary endpoint is met to preserve the
    type I error of the study at 5%
    (1) Proportion of subjects in DA28-CRP Remission at Week 24
    (2) Proportion of subjects in SDAI Remission at Week 52
    (3) Mean change from baseline in TSS at Week 52
    (4) Proportion of subjects in Boolean Remission at Week 52
    Gli endpoint secondari di seguito verranno valutati nell'ordine seguente in modo gerarchico, dopo che l'endpoint primario viene soddisfatto per preservare l'errore di tipo I di studio al 5%

    (1) Proporzione di soggetti in Remissione DA28-CRP alla Settimana 24
    (2) Proporzione di soggetti in Remissione DA28-CRP alla Settimana 52
    (3) Variazione media rispetto al basale in TSS alla Settimana 52
    (4) Proporzione di soggetti in Remissione Boolean alla Settimana 52
    E.5.2.1Timepoint(s) of evaluation of this end point
    (1) Week 24
    (2) Week 52
    (3) Week 52
    (4) Week 52
    (1) Settimana 24
    (2) Settimana 52
    (3) Settimana 52
    (4) Settimana 52
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Biomarkers
    Biomarcatori
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA70
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Austria
    Brazil
    Canada
    Chile
    Colombia
    Czechia
    Finland
    France
    Germany
    Hungary
    Israel
    Italy
    Japan
    Korea, Democratic People's Republic of
    Korea, Republic of
    Mexico
    Netherlands
    Peru
    Poland
    Qatar
    Romania
    Russian Federation
    Saudi Arabia
    Singapore
    South Africa
    Spain
    Sweden
    Taiwan
    United Arab Emirates
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months11
    E.8.9.1In the Member State concerned days14
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months11
    E.8.9.2In all countries concerned by the trial days14
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1350
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 150
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state27
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 580
    F.4.2.2In the whole clinical trial 1500
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    At the end of the treatment periods, BMS will not continue to provide BMS supplied study drug to subjects/investigators unless BMS chooses
    to extend the study. The investigator should ensure that the subject receives appropriate standard of care to treat the condition under study.
    Al termine dei periodi di trattamento, BMS non continuer¿ a fornire BMS fornito farmaco in studio per soggetti / investigatori a meno che BMS scegliesse di estendere lo studio. Lo sperimentatore deve assicurare che il soggetto riceva adeguato standard di cura per trattare le sue condizioni in fase di studio.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-12-04
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-12-17
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA